These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 15848605)
1. Are anemic patients more sensitive to calcineurin inhibitors? Kobayashi T; Kuzuya T; Miwa Y; Liu D; Ma Y; Nagasaka T; Uchida K; Nakao A Transplant Proc; 2005 Mar; 37(2):1005-6. PubMed ID: 15848605 [TBL] [Abstract][Full Text] [Related]
2. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. Bozkaya G; Nart A; Uslu A; Onman T; Aykas A; Doğan M; Karaca B Transplant Proc; 2008; 40(1):151-5. PubMed ID: 18261573 [TBL] [Abstract][Full Text] [Related]
3. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603 [TBL] [Abstract][Full Text] [Related]
4. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948 [TBL] [Abstract][Full Text] [Related]
6. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959 [TBL] [Abstract][Full Text] [Related]
7. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients. Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391 [TBL] [Abstract][Full Text] [Related]
8. Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients. Plank C; Benz K; Amann K; Nüsken KD; Dittrich K; Rascher W; Sauerstein K; Stuppy A; Klare B; Dötsch J Nephrol Dial Transplant; 2006 Oct; 21(10):2930-7. PubMed ID: 16837512 [TBL] [Abstract][Full Text] [Related]
9. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704 [TBL] [Abstract][Full Text] [Related]
10. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372 [TBL] [Abstract][Full Text] [Related]
11. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585 [TBL] [Abstract][Full Text] [Related]
14. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study. Arns W; Zantvoort F; Abendroth D; Seiter H; Scheuermann EH; Albert U; Stahl R; Fornara P; Fricke L; Neumayer HH; Nagel E; Michel U; Ulbricht B Transplant Proc; 2005 Apr; 37(3):1612-5. PubMed ID: 15866687 [TBL] [Abstract][Full Text] [Related]
15. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. Rowshani AT; Scholten EM; Bemelman F; Eikmans M; Idu M; Roos-van Groningen MC; Surachno JS; Mallat MJ; Paul LC; de Fijter JW; Bajema IM; ten Berge I; Florquin S J Am Soc Nephrol; 2006 Jan; 17(1):305-12. PubMed ID: 16306168 [TBL] [Abstract][Full Text] [Related]
16. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values. Troncoso P; Ortiz AM; Jara A; Vilches S Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495 [TBL] [Abstract][Full Text] [Related]
17. Use of cyclosporine in lung transplantation. Parekh K; Trulock E; Patterson GA Transplant Proc; 2004 Mar; 36(2 Suppl):318S-322S. PubMed ID: 15041361 [TBL] [Abstract][Full Text] [Related]